Bristol-Myers Squibb (BMY) Defended at Goldman Sachs

January 24, 2014 3:08 PM

Goldman Sachs reiterated a Conviction Buy Bristol-Myers Squibb Co. (NYSE: BMY) with a price target of $60.00. Comments follow a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found